Somatostatin is a tetradecapeptide with diverse biological effects on cellular functions, including the inhibition of secretory and proliferative processes (Brazeau, 1973; Schally, 1988) . These effects are mediated by specific receptors that belong to the guanine nucleotide binding protein-linked receptor family (Patel et al, 1995) .
In a search for tumour-selective somatostatin analogues, we earlier found that one of our analogues, TT-232 (D-Phe-Cys-DTrp-Lys-Cys-Thr-NH 2 ), exerted a strong antiproliferative effect, but had practically no growth hormone release inhibitory or antisecretory activity (Kéri et al, 1993a (Kéri et al, , 1993b . This compound has a substantially different structure from the growth hormone active analogues (Jaspers et al, 1994) . We have demonstrated that TT-232 exerts a strong in vitro and in vivo anti-tumour activity .
The most frequent form of primary liver cancer is hepatocellular carcinoma, which causes more than 300 000 deaths per year (Ozturk, 1996) . Hepatocellular carcinoma cells are essentially refractory to chemotherapy. The aim of our recent work was to examine whether TT-232 exerts antiproliferative effects on hepatoma cells and whether apoptosis can be triggered in hepatomas. An important part of this work was to test the antiproliferative effect of TT-232 on multidrug-resistant hepatoma cells. We earlier isolated stable, heat-resistant rat hepatoma variants by using repeated heating cycles at 45°C (Venetianer et al, 1994) . These heat-resistant variants became moderately multidrugresistant, they expressed a slightly elevated level of P-gp and an increased basal level of several heat-shock proteins (Venetianer et al, 1994; Pirity et al, 1996) . Highly multidrug-resistant hepatoma variants were also isolated with increasing concentrations of colchicine, these cells strongly overexpressed functional P-gp. Our closely related hepatoma variants representing different Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue degrees of MDR offered a valuable tool to test whether the new somatostatin analogue TT-232 can inhibit cell proliferation or induce apoptosis in the different hepatoma cells.
MATERIALS AND METHODS

Cells lines, media, culture conditions
The culture conditions have been described elsewhere (Venetianer et al, 1980) . Briefly, the cells were grown in F12 (GibcoBRL) medium supplemented with 5% fetal calf serum (BIO MEDIA) in a humidified atmosphere of 8% carbon dioxide in air.
The glucocorticoid-resistant clone 2 cells (Venetianer et al, 1980) were isolated from the glucocorticoid-sensitive, differentiated rat hepatoma Faza 967 clone (Deschatrette and Weiss, 1974) . Clone 2 cells were grown for several years in the presence of 2 µM dexamethasone, and lost the ability to express all liverspecific functions examined, i.e. they became dedifferentiated (Venetianer et al, 1983) .
Stable heat-resistant cells of clone 2 were isolated by ten repeated cycles of heat exposure at 45°C for 80 min. A subclone derived from them and used in the present studies is referred to as clone 2(10×80)T1 (Venetianer et al, 1994) . The heat-resistant derivatives of clone 2 cells were moderately multidrug-resistant. The relative resistance of clone 2(10×80)T1, determined with Trypan blue exclusion test after treatment for 72 h with various concentrations of drugs was the following: 5.2 for vinblastine, 9.4 for doxorubicin, 11.4 for puromycin, 7.7 for actinomycin D and 2.4 for colchicine (Pirity et al, 1996) .
The highly multidrug-resistant variants were isolated from clone 2 cells (clone 2 c1000 ) and from the moderately multidrugresistant clone 2(10×80)T1 (clone 2(10×80)T1 c1000 ) by using stepwise selection with colchicine, and thereafter grown continuously in the presence of 1000 ng ml -1 colchicine. The relative resistance of clone 2 c1000 and clone 2(10×80)T1 c1000 was found to be: 34 and 5.7 for vinblastine, 8.8 and 14.6 for doxorubicin, 65.9 and 65.6 for puromycin, 21.3 and 36.3 for actinomycin D and 37.4 and 40.7 for colchicine respectively (Pirity et al, 1996) . The MDR of the variants correlated with the overexpression of the functional P-gp (Pirity et al, 1996) . The highly multidrug-resistant variants were grown in the absence of colchicine for a week before performing viability tests or other assays.
Cell viability tests
Equal numbers of cells were plated into 35-mm Petri dishes. One day later, the cells were treated with different concentrations of TT-232 and the numbers of viable cells were determined by the Trypan blue exclusion test 24, 48 and 72 h later. For evaluation of the results, it should be considered that in cultured cells the cell membrane does not become permeable to vital dyes in the first and second stages of apoptosis, but only in the third stage; as the membranes rupture, the cells become permeable (Arends and Willie, 1991) .
XTT assay
Equal numbers of cells were plated into 96-well tissue culture plates. One day later, the cells were treated with different concentrations of TT-232. Cell viability was determined in triplicate wells for each drug concentration using the XTT/PMS viability dye assay (Scudiero et al, 1988; Roehm et al, 1991) 24, 48 and 72 h later. Cell viability was expressed as the per cent of absorbance of treated cells relative to the untreated control wells, measured at 450 nm.
The concentrations of drugs which reduced the viability of the treated cells by 50% of that of controls (IC 50 values) were determined using the Trypan blue exclusion test and the XTT assay.
Colony-forming ability after drug exposure
Aliquots of about 1000 dispersed cells were seeded into Petri dishes in triplicates and treated with drugs 16 h later (control cells were not treated); culture media were renewed weekly. Clone 2(10×80)T1 and clone 2(10×80)T1 c1000 cells were grown for 11 days, clone 2 and clone 2 c1000 for 17 days, thereafter the plates were fixed, stained and counted, as described previously (Venetianer et al, 1978; Pirity et al, 1992) .
Assay for induction of apoptosis
A total of 1 × 10 5 (for propidium iodide) or 5 × 10 4 (for cytospin) cells were seeded in 35-mm Petri dishes with or without coverslips and treated with different concentrations of TT-232 1 day later. After exposure, cells seeded on coverslips were fixed, washed and subsequently stained with propidium iodide as described earlier (Bonfoco et al, 1995) . Coverslips were examined either with a Zeiss, Axiovert 135 M confocal laser scanning microscope or with a Leitz fluorescence microscope. Nuclei of untreated cells revealed a typical chromatin morphology with distinct organization, whereas apoptotic nuclei were highly fluorescent, condensed and displayed polarized chromatin aggregates. For quantitative evaluation of apoptotic cells, 20 fields (at least 200 cells) were counted in each preparation. In parallel, the percentage of cells with morphological characteristics of apoptosis and necrosis was determined on a May-Grünwald-Giemsa-stained cytospin preparation (Shandon Elliot cytocentrifuge) by counting at least 400 cells.
Confocal microscopy
Confocal microscopic studies were performed with a Zeiss, Axiovert 135 M, LSM 410 Laser Scan Confocal Microscope and a 100× (N.A. = 1.5, oil) objective. The z-axis position was fixed so that the optical section clearly transected the nuclei. Fluorescence was excited by using an argon ion laser at 488 nm (15 mW). Nuclei area measurements for at least 20 randomly selected fields of propidium iodide-stained TT-232-treated and control cells were performed using the LSM software, which is based on the Microsoft Windows graphical user interface.
DNA ladder assay
Clone 2 and clone 2(10×80)T1 c1000 cells were treated with 30 µg ml -1 TT-232 for 21 h; control cells were not treated. As an internal control for ladder formation, drug-sensitive clone 2 cells were treated with 60 ng ml -1 , highly drug-resistant clone 2(10×80)T1 c1000 cells with 600 ng ml -1 actinomycin D for 21 h. Fragmented DNA was separated from intact DNA, extracted and loaded onto agarose gels as described earlier (Laurent-Crawford et al, 1991) . PstI-digested λ DNA was used as molecular weight marker.
Measurement of intracellular doxorubicin concentration
Hepatoma cells were exposed to 10 µM doxorubicin for 4 h, in the presence or absence of 10 µg ml -1 TT-232. The intracellular concentration of doxorubicin was determined as described previously (Fardel et al, 1993) .
Peptides
TT-232 (D-Phe-Cys-Try-D-Trp-Lys-Cys-Thr-NH 2 ) was synthetized in our laboratory as described earlier (Kéri et al, 1993a) then, 2 mg ml -1 TT-232 stock solution was prepared by dissolving TT-232 in 0.2 M acetic acid-sodium acetate buffer, pH 3.45 adjusted to 5% mannit (w/v) and stored at 4°C up to 1 month. Before use the TT-232 stock solution was diluted in culture medium. The vehicle was also added to control cultures. Chemicals were obtained from Sigma.
RESULTS
In vitro antiproliferative effect of TT-232 on hepatoma cell lines
XTT assay was used to compare the cytotoxicity of TT-232 on different variants. Cells were treated with different concentrations of TT-232 for 3 days. IC 50 values determined at least in three independent experiments were the following: 14 ± 1.8 µg ml -1 for clone 2, 10 ± 0.7 µg ml -1 for clone 2(10×80)T1, 12 ± 1.1 µg ml -1 for clone 2(10×80)T1 c1000 and 12 ± 1.5 for the drug-sensitive, differentiated Faza 967. The effect of TT-232 on cell viability was also determined using the Trypan blue exclusion test following a 1-day treatment. The IC 50 were found to be between 45 and 54 µg ml -1 (54 ± 3 µg ml -1 for clone 2; 53 ± 4 µg ml -1 for clone 2 c1000 ; 45 ± 3 µg ml -1 for clone 2(10×80)T1; 45 ± 4 µg ml -1 for clone 2(10×80)T1 c1000 ; and 46 ± 3 µg ml -1 for Faza 967 clone).
To examine the long-term effects of TT-232 on different hepatomas, the cells were treated continuously up to 17 days with the hormone analogue and the extents of colony formation were compared. While 10 µg ml -1 TT-232 had no or only a slight effect on colony formation, 15 µg ml -1 drastically inhibited colony formation in all hepatoma variants (Figure 1 ).
The results of the different assays clearly show that TT-232 inhibits the proliferation and viability of all examined hepatoma cells and the inhibition is dose-and time-dependent. These experiments reveal that the sensitivity of moderately-and highly multidrug-resistant variants to TT-232 was not reduced.
TT-232 induces apoptosis in drug-sensitive and multidrug-resistant cells
In an attempt to characterize the mechanisms responsible for the cytotoxicity of TT-232 on hepatoma cells, we tested the possible apoptosis-inducing effect of the hormone analogue. Treatment of hepatoma cells with TT-232 induced the typical apoptotic morphology in both drug-sensitive (Figure 2A, B) and multidrugresistant cells (Figure 2C, D) . To determine the ratio of apoptotic and necrotic cells the variants were treated with TT-232 for 1, 2 and 3 days. The percentage of cells with morphological characteristics of apoptosis was determined on coverslips following propidium iodide staining and in May-Grünwald-Giemsa-stained cytospin preparations. Necrosis occurred at much lower rates than apoptosis in all TT-232-treated cells; 20 µg ml -1 TT-232 induced approximately 20-40% apoptosis and 9-12% necrosis after treatment for 1 day, 30-60% apoptosis and 3-17% necrosis after treatment for 2 days, and 40-70% apoptosis and 9-28% necrosis after treatment for 3 days. Figure 2E , F depicts the percentages of apoptotic and necrotic cells in clone 2, clone 2 c1000 and clone 2(10×80)T1 c1000 cells following treatment with TT-232 for 3 days. It is clear from the results that the MDR of hepatomas is not correlated with a reduced susceptibility to apoptosis induction by TT-232.
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The apoptosis-inducing effect of TT-232 was also examined by measuring the areas of propidium iodide-stained nuclei with LSM software. During apoptosis, cell shrinkage and chromatin condensation occurred. Treatment of the hepatoma cells with TT-232 for 1, 2 and 3 days resulted in clear decreases in the areas of the nuclei. While the area of nuclei of the majority of control cells was around 300 µm 2 , it was much lower, with highest frequencies around 140 µm 2 , following treatment with 20 µg ml -1 TT-232 for 3 days (Figure 3) . A similar reduction in the size of the treated nuclei was seen for the highly drug-resistant hepatoma clone 2 c1000 (Figure 3) .
To learn whether treatment with increasing concentrations of TT-232 induces apoptosis in a dose-dependent manner, the drugsensitive and resistant cells were treated with different concentrations of TT-232 for 1 day. The percentage of apoptotic cells increased in all hepatomas with increasing concentration of TT-232 and was between 60 and 75% at 60 µg ml -1 TT-232, while the percentage of necrotic cells was significantly lower. These results reveal that the apoptosis-inducing effect of TT-232 is dose and time-dependent.
Induction of DNA fragmentation in response to TT-232 treatment
One of the earliest steps in apoptosis appears to be DNA digestion. Apoptosis is usually associated with the activation of nucleases that degrade the chromosomal DNA first into large, and subsequently into very small, oligonucleosomal fragments.
Clone 2 and the multidrug-resistant cells were treated with 30 µg ml -1 TT-232 for 21 h. For comparison, the cells were also treated with actinomycin D, which induces apoptosis and DNA ladder formation in these cells (unpublished results). A characteristic pattern of DNA fragments was observed in both drugsensitive and resistant cells, which consisted of multimers of approximately 180 base pairs. A typical DNA fragmentation pattern is shown in Figure 4 .
TT-232 is not a substrate of P-glycoprotein
We reported earlier that the overexpression of P-gp in both moderately and highly multidrug-resistant hepatoma variants correlated 
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Figure 3 Nuclear area distribution in clone 2 and clone 2 c1000 cells following treatment with 20 µg ml -1 TT-232 for 1, 2 and 3 days. Nuclei area measurements for at least 20 randomly selected fields were performed by using LSM software as described above. (A, C) Clone 2, clone 2 c1000 control; (B, D) clone 2, clone 2 c1000 treated with a decreased accumulation of anticancer drugs, such as doxorubicin (Pirity et al, 1996) . Addition of verapamil, a calcium channel blocker drug known to reverse MDR by inhibiting P-gp function, significantly increased the cellular doxorubicin accumulation. Addition of TT-232, however, had no effect on the doxorubicin retention. The intracellular concentration of doxorubicin in the absence and presence of 10 µg ml -1 TT-232 was found to be: 38.5 ± 4 and 39.5 ± 4 µM mg -1 protein in clone 2, and 1.2 ± 0.1 and 1.3 ± 0.1 µM mg -1 in clone 2(10×80)T1 c1000 cells), indicating that TT-232 is not a substrate for P-gp.
DISCUSSION
A structural analogue of somatostatin (TT-232) has been developed in our laboratory. TT-232 has been tested on various human tumour cell lines by the National Cancer Institute of NIH. It was found that 100 µM of TT-232 had a strong antiproliferative effect on the majority of cell lines. We recently reported that TT-232 induced apoptosis in different human tumour cell lines . In vivo, TT-232 was effective on transplanted animal tumours (COLO26, B16 melanoma and S180 sarcoma) and on human tumour xenografts . We found, for example, that 30% of S180 tumour-bearing mice treated twice daily intraperitonially with low dose (15 µg kg -1 ) of TT-232 for 12 days became tumour-free, while continuous administration of the drug resulted in 60% tumour-free animals (Kéri et al, 1997) . Our data suggest that TT-232 is a promising anti-tumour agent.
Primary cancer of the liver is the fourth most common cause of death from cancer (Ozturk, 1996) . Hepatocellular carcinomas generally do not respond well to chemotherapy. Numerous mechanisms of drug resistance are well established for tumour cells in vitro (Fisher, 1994) . The main goal of cancer chemotherapy is to kill tumour cells, but not their normal counterparts, with specific antineoplastic drugs. One promising way for doing this is to induce the genetically encoded death programme in cancer cells, including the multidrug-resistant tumour cells.
In this report, we have demonstrated for the first time that TT-232 has pronounced antiproliferative effects on hepatocellular carcinoma cell lines, including differentiated and dedifferentiated, drug-sensitive and multidrug-resistant hepatomas. Long-term treatment of the hepatomas with 15 µ ml -1 TT-232 drastically inhibited colony formation in all examined hepatoma variants. The IC 50 values determined by the Trypan blue exclusion test were in the range 40-50 µM, indicating comparable sensitivities of the variants. The IC 50 values for breast, colon and prostate lines were in the range 20-40 µM .
The most important finding in our experiments was that TT-232 induces apoptosis in all examined hepatoma variants. Treatments of hepatoma cells with TT-232 induced a typical apoptotic morphology, with a clear decrease in the areas of the nuclei and a characteristic pattern of DNA fragmentation. The major form of cell death occurring in the different hepatoma variants was apoptosis. The percentages of apoptotic cells were comparable following treatment with TT-232 in the drug-sensitive and highly multidrug-resistant hepatomas. Multidrug-resistant hepatoma variants overexpressing functional P-gp were found not to be less sensitive to TT-232 than the P-gp non-expressing, drug-sensitive cells. These observations can be explained by our observations showing that TT-232 is not a substrate of P-gp. These results clearly reveal that the machinery involved in apoptosis is functional both in drug-sensitive and in drug-resistant hepatoma variants, and it can be activated by the somatostatin analogue TT-232.
Our earlier results showed that the basal expression of several heat-shock proteins was increased in the heat-resistant, moderately multidrug-resistant hepatoma variants and in the highly multidrugresistant derivatives of them (Venetianer et al, 1994; Pirity et al, 1996) . Heat-shock proteins play an important role in protecting cells from the harmful effects of stress (Morimoto et al, 1990 ) and could also protect cells from apoptotic cell death (Mosser et al, 1992; Mehlen et al, 1996) . Our data presented in this paper indicate that the observed increased basal expression of Hsp27 and Hsp70 did not prevent the initiation of apoptotic pathway in hepatoma cells treated with TT-232.
In recent years, considerable effort has been directed towards the development of small molecular tyrosine kinase inhibitors as potential anti-tumour drugs (Levitzki and Gazit, 1995) . It was demonstrated that somatostatin and other pepide hormones and analogues, which inhibit tyrosine kinase activity, can also induce apoptosis . Although we could not measure the inhibitory effect of TT-232 on the tyrosine kinase activity of our hepatoma cells, due to the low basal activity of the enzyme, we observed that the apoptosis-inducing effect of a recently described, very potent tyrosine kinase inhibitor, which is a quinazoline derivative (PD153035; Fry et al, 1994) , on multidrug-resistant hepatoma cells is comparable to that of TT-232 (unpublished results).
Our recent finding showing that TT-232 can kill not only hepatocellular carcinoma cells, but also the multidrug-resistant variants by apoptosis together with our earlier data demonstrating strong in vivo anti-tumour activity at relatively low doses, and the results of toxicity studies suggest that TT-232 is a promising antitumour agent. 
